Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Grieve

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 25, 2007
Combined modality treatment of early rectal cancer: the UK experienceA Sun Myint, R J Grieve, A C McDonald, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 6, 2012
A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancerD Spooner, D D Stocken, S Jordan, et al.
British Journal of Haematology|September 13, 2001
T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvementE Olavarria, F Child, A Woolford, et al.
The British Journal of Surgery|January 29, 2014
Observations from the IMPROVE trial concerning the clinical care of patients with ruptured abdominal aortic aneurysm, J T Powell, R J Hinchliffe, et al.
Breast Cancer Research and Treatment|March 12, 2011
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancerR Coleman, E Woodward, J Brown, et al.
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
British Journal of Cancer|September 18, 2008
NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of lifeH M Earl, L Hiller, J A Dunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 1998
Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma GroupN P Bailey, N S Stuart, E M Bessell, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 25, 2007
Combined modality treatment of early rectal cancer: the UK experienceA Sun Myint, R J Grieve, A C McDonald, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 6, 2012
A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancerD Spooner, D D Stocken, S Jordan, et al.
British Journal of Haematology|September 13, 2001
T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvementE Olavarria, F Child, A Woolford, et al.
The British Journal of Surgery|January 29, 2014
Observations from the IMPROVE trial concerning the clinical care of patients with ruptured abdominal aortic aneurysm, J T Powell, R J Hinchliffe, et al.
Breast Cancer Research and Treatment|March 12, 2011
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancerR Coleman, E Woodward, J Brown, et al.
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
British Journal of Cancer|September 18, 2008
NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of lifeH M Earl, L Hiller, J A Dunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 1998
Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma GroupN P Bailey, N S Stuart, E M Bessell, et al.
Pageof 4